Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/ refractory (R/R) multiple myeloma (MM)

Category Primary study
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 0212f02d2f6fede476cabceeb26db7ffe1223548
First added on: Feb 14, 2025